Medtronic is initiating a study to see whether a technology it developed for treating diabetes might also help patients with the hepatitis C virus.
The Medtronic Paradigm Infusion System is an external pump infusion system currently approved for delivering insulin in patients with diabetes.
The company announced today that it’s started enrolling patients in a clinical study to test the tolerability, safety and effectiveness of using the system to deliver hepatitis C medication.
“With this trial now under way, we have the potential to extend our pump technologies and develop yet another drug-delivery option for a chronic disease that impacts millions of lives,” CEO Bill Hawkins said.
Chronic hepatitis patients can require weekly injections plus oral medication for up to 48 weeks. Medtronic hopes the continuous-delivery system might be more convenient with fewer side effects.